Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

Cited by (606)

Items 101–200 of 606

1. Novel amphiphilic chitosan nanocarriers for sustained oral delivery of hydrophobic drugs
   Marjan Motiei, Soheila Kashanian · 2017 · European Journal of Pharmaceutical Sciences
2. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
   Zaida García‐Casado, Ángel Guerrero Zotano, Antonio Llombart‐Cussac, Ana M Calatrava, Antonio Fernández‐Serra, Amparo Ruiz-Simón, Joaquín Gavilá, Miguel Ángel Climent, Sergio M. Almenar, José Cervera-Deval et al. · 2010 · BMC Cancer
3. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP‐2 and MMP‐9) by human epithelial breast cancer cells
   Theoni N. Mitropoulou, George N. Tzanakakis, Dimitris Kletsas, Haralabos P. Kalofonos, Nikos K. Karamanos · 2003 · International Journal of Cancer
4. Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
   Sally J. Ioannides, Philip L. Barlow, Mark Elwood, D. Porter · 2014 · Breast Cancer Research and Treatment
5. Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch
   Pooja Ratre, Keerti Mishra, Amit Dubey, Amber Vyas, Akhlesh Kumar Jain, Suresh Thareja · 2020 · Anti-Cancer Agents in Medicinal Chemistry
6. Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer
   Brent P. Zabolotny, Christian V. Zalai, Sarkis H. Meterissian · 2005 · Journal of Surgical Oncology
7. Long-term safety of aromatase inhibitors in the treatment of breast cancer
   Jean Marc Nabholtz · 2008 · Therapeutics and Clinical Risk Management
8. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer
   H. Aguilar, Xavier Solé, Núria Bonifaci, Jordi Serra-Musach, Abul Bashar Mir Md. Khademul Islam, Núria López-Bigas, Marinela Méndez‐Pertuz, Roderick L. Beijersbergen, Conxi Lázaro, Ander Urruticoechea et al. · 2010 · Oncogene
9. Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism
   Atul Purohit, L. W. Lawrence Woo, Barry V. L. Potter · 2011 · Molecular and Cellular Endocrinology
10. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women
    Henning T. Mouridsen · 2006 · Current Medical Research and Opinion
11. Selective Dual Inhibitors of CYP19 and CYP11B2: Targeting Cardiovascular Diseases Hiding in the Shadow of Breast Cancer
    Qingzhong Hu, Lina Yin, Rolf W. Hartmann · 2012 · Journal of Medicinal Chemistry
12. Oestrogen Synthesis in the Hippocampus: Role in Axon Outgrowth
    C. Von Schassen, Lars Fester, Janine Prange‐Kiel, C. Lohse, Cornelia Huber, Martina Böttner, Gabriele M. Rune · 2006 · Journal of Neuroendocrinology
13. Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation
    Per Eystein Lønning, Ben P. Haynes, Anne Hege Straume, Anita K. Dunbier, Hildegunn Helle, Stian Knappskog, Mitch Dowsett · 2011 · Clinical Cancer Research
14. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples
    Jürgen Geisler, Dagfinn Ekse, Hildegunn Helle, Nhat K. Duong, Per Eystein Lønning · 2008 · The Journal of Steroid Biochemistry and Molecular Biology
15. Influence of sex steroids on inflammation and bone metabolism
    Harlan J. Shiau, Mary Elizabeth Aichelmann‐Reidy, Mark Allan Reynolds · 2013 · Periodontology 2000
16. The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
    Nina Gran Egeland, Siri Lunde, Kristín Jónsdóttir, Tone Hoel Lende, Deirdre P Cronin-Fenton, Bjørnar Gilje, Emiel A. M. Janssen, Håvard Søiland · 2015 · International Journal of Molecular Sciences
17. Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
    Kathrin Strasser‐Weippl, Paul Edward Goss · 2005 · Journal of Clinical Oncology
18. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
    Michaela Jane Higgins, Tatiana Michelle Prowell, Amanda L. Blackford, Celia Byrne, Nagi F. Khouri, Shannon A. Slater, Stacie C. Jeter, Deborah Kay Armstrong, Nancy E. Davidson, Leisha A. Emens et al. · 2011 · Breast Cancer Research and Treatment
19. Treatment of symptomatic uterine leiomyoma with letrozole
    Bilgin Gürateş, Cem Parmaksız, Gokhan Sami Kilic, Hüsnü Çelik, Selahattin Kumru, Mehmet Şimşek · 2008 · Reproductive BioMedicine Online
20. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials
    Lisa Rydén, Marianne Heibert Arnlind, Sigurd Vitols, Malin Höistad, Johan Ahlgren · 2016 · The Breast
21. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations
    Jürgen Geisler, Per Eystein Lønning · 2005 · The Journal of Steroid Biochemistry and Molecular Biology
22. The causes and treatment of bone loss associated with carcinoma of the breast
    J LESTER, David John Dodwell, Eugene Vincent McCloskey, R COLEMAN · 2005 · Cancer Treatment Reviews
23. Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
    Anthony Howell, Mitch Dowsett · 2004 · Breast Cancer Research
24. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Brian J. Long, Danijela Jelovac, Apinya Thiantanawat, Angela M. H. Brodie · 2002 · PubMed
25. Hippocampal estradiol synthesis and its significance for hippocampal synaptic stability in male and female animals.
    R. Vierk, Nicola Brandt, G. Rune · 2014 · Neuroscience
26. Aromatase inhibitors in the breast cancer clinic: focus on exemestane
    Kathleen Van Asten, Patrick Neven, Anneleen Lintermans, Hans P. M. W. Wildiers, Robert Paridaens · 2014 · Endocrine Related Cancer
27. Estrogen as therapy for breast cancer
    James N. Ingle · 2002 · Breast Cancer Research
28. Letrozole in the extended adjuvant setting: MA.17
    Paul Edward Goss · 2007 · Breast Cancer Research and Treatment
29. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
    Georg Pfeiler, Robert Königsberg, Peyman Hadji, Florian Fitzal, M Maroske, G Dressel-Ban, J Zellinger, Ruth Exner, Michael Seifert, Christian Fridolin Singer et al. · 2013 · British Journal of Cancer
30. Effects of hormonal treatment on lipids in patients with cancer
    Theodosios D. Filippatos, Evangelos N. Liberopoulos, Nikolaos Pavlidis, Moses Elisaf, Dimitri P. Mikhailidis · 2008 · Cancer Treatment Reviews
31. Tumor-Stromal Interaction through the Estrogen-Signaling Pathway in Human Breast Cancer
    Yuri Yamaguchi, Hiroyuki Takei, Kimito Suemasu, Yasuhito Kobayashi, Masafumi Kurosumi, Nobuhiro Harada, Shin‐ichi Hayashi · 2005 · Cancer Research
32. Prevalence of Secondary Causes of Bone Loss Among Breast Cancer Patients With Osteopenia and Osteoporosis
    Pauline M. Camacho, Amit S. Dayal, Josefina Diaz, Fadi A. Nabhan, Monica Agarwal, John Norton, Patricia A. Robinson, Kathy S. Albain · 2008 · Journal of Clinical Oncology
33. Neuroprotection by estradiol: A role of aromatase against spine synapse loss after blockade of GABAA receptors
    Lepu Zhou, Nadine Lehan, Uwe Wehrenberg, Erik M. Disteldorf, Richard von Lossow, Ute Mares, Hubertus Jarry, Gabriele M. Rune · 2006 · Experimental Neurology
34. Aromatase Inhibitors: Rationale and Use in Breast Cancer
    Cynthia Osborne, Debu Tripathy · 2005 · Annual Review of Medicine
35. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications
    Toru Hanamura, Shin‐ichi Hayashi · 2017 · Breast Cancer
36. Update on the use of aromatase inhibitors in breast cancer
    Robert W. Brueggemeier · 2006 · Expert Opinion on Pharmacotherapy
37. Steroid sulfatase inhibitors: promising new tools for breast cancer therapy?
    Geisler, Jürgen, Sasano, Hironobu, Chen, Shiuan, Purohit, Atul · 2011 · The Journal of Steroid Biochemistry and Molecular Biology
38. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole
    William R. Miller, Alexey A. Larionov, Thomas James Anderson, Dean B. Evans, J. Michael Dixon · 2010 · The Pharmacogenomics Journal
39. A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
    Lee Steven Schwartzberg, Denise Aysel Yardley, ANTHONY D. ELIAS, Manish R. Patel, Patricia Mucci LoRusso, Howard A. Burris, Ayca Gucalp, Amy Peterson, Martha Elizabeth Blaney, Joyce Steinberg et al. · 2017 · Clinical Cancer Research
40. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies
    Robert Edward Coleman, Jean-Jacques Body, Julie R. Gralow, Allan Lipton · 2008 · Cancer Treatment Reviews
41. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition
    Hero, Matti, Ankarberg-Lindgren, Carina, Taskinen, Marja-Riitta, Dunkel, Leo · 2006 · European Journal of Endocrinology
42. Tetrahydropyrroloquinolinone Type Dual Inhibitors of Aromatase/Aldosterone Synthase as a Novel Strategy for Breast Cancer Patients with Elevated Cardiovascular Risks
    Lina Yin, Qingzhong Hu, Rolf W. Hartmann · 2013 · Journal of Medicinal Chemistry
43. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
    Paul Edward Goss, Dawn L. Hershman, Angela M. Cheung, James N. Ingle, Sundeep Khosla, Vered Stearns, Haji Ibraheem Chalchal, Kendrith M. Rowland, Hyman Bernard Muss, Hannah M. Linden et al. · 2014 · The Lancet Oncology
44. To Block Estrogen's Synthesis or Action: That Is the Question
    Richard J. Santen · 2002 · The Journal of Clinical Endocrinology & Metabolism
45. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
    Iben Kümler, Ann Søegaard Knoop, Christina Jessing, Bent Ejlertsen, Dorte Lisbet Nielsen · 2016 · ESMO Open
46. Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors
    Natalie J. Engmann, Christopher G. Scott, Matthew R. Jensen, Lin Ma, Kathleen R. Brandt, Amir Pasha Mahmoudzadeh, Serghei Malkov, Dana H. Whaley, Carrie B. Hruska, Fang Wu et al. · 2017 · Cancer Epidemiology Biomarkers & Prevention
47. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels
    Jürgen Geisler, Ben P. Haynes, Dagfinn Ekse, Mitch Dowsett, Per Eystein Lønning · 2007 · The Journal of Steroid Biochemistry and Molecular Biology
48. The biology of steroid hormones and endocrine treatment of breast cancer
    Mitch Dowsett, Elizabeth J. Folkerd, Deborah Doody, Ben P. Haynes · 2005 · The Breast
49. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study
    Yasuo Hozumi, Kimito Suemasu, H. Takei, Tomohiko Aihara, Megumi Takehara, Tsuyoshi Saito, Shozo Ohsumi, Norikazu Masuda, Yasuo Ohashi · 2011 · Annals of Oncology
50. Interpreting Plasma Estrogen Levels in Breast Cancer: Caution Needed
    Elizabeth J. Folkerd, Per Eystein Lønning, Mitch Dowsett · 2014 · Journal of Clinical Oncology
51. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
    Per Eystein Lønning · 2008 · European Journal of Cancer
52. Anastrozole
    Mark Sanford, Greg L. Plosker · 2008 · Drugs
53. Anti-oestrogenic prevention of breast cancer — the make or break point
    Trevor J. Powles · 2002 · Nature reviews. Cancer
54. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer
    Neill Patani, Lesley‐Ann Martin · 2013 · Molecular and Cellular Endocrinology
55. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
    In Hae Park, Yeon-Su Lee, Keun Seok Lee, Soo-kyoung Kim, Seung-Hyun Hong, Jae-Heon Jeong, Hyewon Lee, Jungsil Ro, Byung‐Ho Nam · 2011 · Cancer Chemotherapy and Pharmacology
56. Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines
    Adriana Reis Brandão Matutino, Anil Abraham Joy, Christine Brezden‐Masley, S. Chia, Sunil Verma · 2018 · Current Oncology
57. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos
    Golara Golbaghi, Irène Pitard, Matthieu Lucas, Mohammad Mehdi Haghdoost, Yossef López de los Santos, Nicolas Doucet, Shunmoogum A. Patten, J. Thomas Sanderson, Annie Castonguay · 2020 · European Journal of Medicinal Chemistry
58. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
    Richard J. Santen, Ran Song, Z Zhang, Rakesh Kumar, Meei Huey Jeng, Shigeru Masamura, W Yue, Lev M. Berstein · 2003 · Endocrine Related Cancer
59. Administration of an inhibitor of estrogen biosynthesis facilitates working memory acquisition in male rats
    Misael Alejandre-Gómez, Luis Miguel García‐Segura, Ignacio González‐Burgos · 2007 · Neuroscience Research
60. Cancer Treatment-Related Bone Disease
    Sue A. Brown, Theresa A. Guise · 2009 · Critical Reviews in Eukaryotic Gene Expression
61. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
    Henning T. Mouridsen, Nicholas J. Robert · 2004 · European Journal of Cancer
62. Challenges in the endocrine management of breast cancer
    Henning T. Mouridsen, Carsten Rose, Angela Brodie, Ian E. Smith · 2003 · The Breast
63. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors
    Allison Marie Quick, Filadelfiya Zvinovski, Catherine O. Hudson, Andrew F. Hundley, Cynthia Duggan Evans, Anupama Suresh, Julie A. Stephens, Elizabeth Kinkade Arthur, Bhuvaneswari Ramaswamy, Raquel E. Reinbolt et al. · 2019 · Supportive Care in Cancer
64. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study
    Norah Lynn Henry, Dmitri Pchejetski, Roger A’Hern, Anne Nguyen, Peter J Charles, Jonathan Waxman, Lang Li, Anna Maria Storniolo, Daniel F. Hayes, David Alastair Flockhart et al. · 2010 · British Journal of Cancer
65. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane
    Ángel Guerrero, J.G. Gavila, Elizabeth J. Folkerd, B. Ortiz, F. Martínez, Agustin A. García, M.A. Climent, Vicente Guillém, A. Ruíz · 2012 · Annals of Oncology
66. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
    Marianne Hauglid Flågeng, Line L. Haugan Moi, J. Michael Dixon, Jürgen Geisler, Ernst Asbjorn Lien, William R. Miller, Per Eystein Lønning, Gunnar Mellgren · 2009 · British Journal of Cancer
67. Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
    Reva Schneider, Ayman Barakat, John Pippen, Cynthia R. C. Osborne · 2011 · Breast Cancer Targets and Therapy
68. Friend or foe: Multiple roles of adipose tissue in cancer formation and progression
    Yuxiang Wang, Neng Zhu, Chanjuan Zhang, Yikai Wang, Hong‐Tao Wu, Qun Li, Ke Du, Duan‐Fang Liao, Qin Li · 2019 · Journal of Cellular Physiology
69. Update on the Role of Aromatase Inhibitors in Growth Disorders
    Leo Dunkel · 2009 · Hormone Research in Paediatrics
70. Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients
    Alka Verma, Justin C. Konje · 2009 · European Journal of Obstetrics & Gynecology and Reproductive Biology
71. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
    Khalil Zaman, Beat J. K. Thurlimann, Jens Huober, A. Schönenberger, Olivia Pagani, Jean‐Christophe Luthi, Mathew Simcock, Anita Giobbie‐Hurder, Grégoire Berthod, Claude Yves Genton et al. · 2011 · Annals of Oncology
72. A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer
    Deborah Fenlon, Julia M Addington-Hall, Alison C. O’Callaghan, JOANNE B. CLOUGH, PETER G. NICHOLLS, Peter Simmonds · 2013 · Journal of Pain and Symptom Management
73. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
    Gianfilippo Bertelli, Emma Hall, Elizabeth Ireland, Claire F. Snowdon, Jacek Jassem, Kazimierz Drosik, H Karnicka-Młodkowska, R. Charles Coombes, Judith M. Bliss · 2009 · Annals of Oncology
74. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors
    Yu Xuan Gu, Tianxiang Chen, Elena López‐Camacho, Weizhu Wu, Xiangdong Wang, Jiang Cao, Lisong Teng · 2014 · Journal of Translational Medicine
75. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    Richard Sainsbury · 2004 · British Journal of Cancer
76. Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole
    Lauren Nicole Bell, Anne Nguyen, Lang Li, Zeruesenay Desta, Norah Lynn Henry, Daniel F. Hayes, Antonio C. Wolff, Vered Stearns, Anna Maria Storniolo, David Alastair Flockhart · 2011 · The Journal of Clinical Pharmacology
77. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer
    Luis Jesus Schwarz, Emily M. Fox, Justin Micah Balko, Joan T. Garrett, Maria Gabriela Kuba, Monica Valeria Estrada, Ana Maria Gonzalez-Angulo, Gordon Brent Mills, Monica Red-Brewer, Ingrid A. Mayer et al. · 2014 · Journal of Clinical Investigation
78. Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model
    Majorie B.M. van Duursen, Evelien E.J.W. Smeets, Jeroen C.W. Rijk, Sandra M. Nijmeijer, Martin van den Berg · 2013 · Toxicology and Applied Pharmacology
79. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
    Peyman Hadji, Robert Edward Coleman, Michael Gnant, J. Green · 2012 · Annals of Oncology
80. Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities
    Maria A Dominguez-Cejudo, Ana Gil-Torralvo, Mónica Cejuela Solís, Sonia Molina‐Pinelo, Javier Salvador Bofill · 2023 · International Journal of Molecular Sciences
81. Aromatase Inhibition Exacerbates Pain and Reactive Gliosis in the Dorsal Horn of the Spinal Cord of Female Rats Caused by Spinothalamic Tract Injury
    Samar Ghorbanpoor, Luis Miguel García‐Segura, Ali Haeri-Rohani, Fariba Khodagholi, Masoumeh Jorjani · 2014 · Endocrinology
82. Endocrine changes, fetal growth, and uterine artery hemodynamics after chronic estrogen suppression during the last trimester of equine pregnancy†
    Alejandro Esteller‐Vico, Barry A. Ball, Mats H.T. Troedsson, E.L. Squires · 2017 · Biology of Reproduction
83. Approaches to Vaginal Bleeding and Contraceptive Counseling in Transgender and Gender Nonbinary Patients
    Amanda Rae Schwartz, Kristen Russell, Beverly Gray · 2019 · Obstetrics and Gynecology
84. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
    James N. Ingle, Junmei Cairns, Vera Jean Suman, Lois E. Shepherd, Peter Andreas Fasching, Tanya L. Hoskin, Ravinder Jit Singh, Zeruesenay Desta, Krishna R. Kalari, Matthew J. Ellis et al. · 2020 · Clinical Cancer Research
85. Aromatase inhibitors in breast cancer
    Stephen Hiscox, Emma Davies, Peter J. Barrett-Lee · 2009 · Maturitas
86. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer
    T. Tominaga, I Adachi, Yo Sasaki, Toshio Tabei, T. Ikeda, Yoshifusa Takatsuka, Masakazu Toi, Toshikazu Suwa, Yasuo Ohashi · 2002 · Annals of Oncology
87. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
    Kimberly Blackwell, Howard A. Burris, Patricia Gómez, Norah Lynn Henry, Steven Jay Isakoff, Frank Campana, Lei Gao, Jason Jiang, Sandrine Macé, Sara M. Tolaney · 2015 · Breast Cancer Research and Treatment
88. Therapeutic Options for Metastatic Breast Cancer
    Manpreet Sambi, Bessi Qorri, William W. Harless, Myron R. Szewczuk · 2019 · Advances in experimental medicine and biology
89. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer
    John Berry · 2005 · Clinical Therapeutics
90. Bone markers and current laboratory assays
    Rosernary A. Hannon, Richard Eastell · 2006 · Cancer Treatment Reviews
91. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy
    Lisa M. Gallicchio, Ryan MacDonald, Bethany Wood, Errol Rushovich, Kathy J. Helzlsouer · 2011 · Breast Cancer Research and Treatment
92. An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range
    Bjørn-Erik Bertelsen, Ralf Kellmann, Kristin Viste, Anne Turid Bjørnevik, Hans Petter Eikesdal, Per Eystein Lønning, Jørn Vegard Sagen, Bjørg Almås · 2020 · Journal of the Endocrine Society
93. Role of aromatase inhibitors in the treatment of breast cancer
    Toni K. Choueiri, Carlos A. Alemany, Rony M. Abou-Jawde, George Thomas Budd · 2004 · Clinical Therapeutics
94. Germline Genetic Predictors of Aromatase Inhibitor Concentrations, Estrogen Suppression and Drug Efficacy and Toxicity in Breast Cancer Patients
    Daniel L. Hertz, Norah Lynn Henry, James Michael Rae · 2017 · Pharmacogenomics
95. Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer
    Zara F. Ghazoui, Francesca Meteora Buffa, Anita K. Dunbier, H Anderson, Tim Dexter, Simone I. DETRE, Janine Salter, Ian E. Smith, Adrian Llewellyn Harris, Mitch Dowsett · 2011 · Clinical Cancer Research
96. Letrozole
    Silvia Dellapasqua, Marco Angelo Colleoni · 2010 · Expert Opinion on Drug Metabolism & Toxicology
97. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors
    Per Eystein Lønning, Benjamin P. Haynes, Mitch Dowsett · 2014 · European Journal of Cancer
98. Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance
    Cynthie Wong, Shiuan Chen · 2009 · Cancer Research
99. Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole
    Robert Thomas, Sara Godward, Andreas Makris, David J. Bloomfield, Anne Margaret Moody, M Williams · 2004 · Clinical Oncology
100. Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis
     Jingxuan Wang, Zhang Qingyuan, Jin Fa Shi, Meiyan Feng, Kang Xinmei, Shu Zhao, Shuling Liu, Wenhui Zhao · 2009 · Experimental Gerontology